The promises and perils of circulating tumor DNA for monitoring immunotherapy response in non-small cell lung cancer
Brandon Joseph Hebert, James Bradley, Nicola Normanno · 2024
Read The promises and perils of circulating tumor DNA for monitoring immunotherapy response in non-small cell lung cancer by Brandon Joseph Hebert, James Bradley, Nicola Normanno (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11702262.txt.
Description
Brandon Joseph Hebert and James Bradley weigh blood-borne tumor DNA for tracking immunotherapy in a 2024 review. Immune checkpoint drugs have transformed lung cancer care, but few patients respond, and the drugs are costly and toxic. A blood test that forecasts response would spare many a futile course. Fragments of tumor DNA circulating in blood promise exactly that: non-invasive, personal, and live.
Large studies already link the fragments' behavior to how patients fare on immunotherapy, and an intervention trial is testing whether acting on the signal helps. The authors also catalog the catches: other illnesses muddy the signal, the tumor fraction varies, stage matters, and blood findings can disagree with tissue. Clinicians, they argue, should learn the limits before the test becomes routine.
Catalog record
| CREATOR | Brandon Joseph Hebert, James Bradley, Nicola Normanno |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 20 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |